Trial Profile
SPONTANEOUS STUDY WITH ADJUVANT TRASTUZUMAB HERCEPTIN IN WOMEN WITH HER-2 POSITIVE PRIMARY BREAST CANCER WHO HAVE COMPLETED ADJUVANT CHEMOTHERAPY.
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 26 May 2011
Price :
$35
*
At a glance
- Drugs Trastuzumab (Primary)
- Indications Breast cancer
- Focus Therapeutic Use
- Acronyms HERMA
- 26 May 2011 New trial record